Back to top
more

Omnicell (OMCL)

(Delayed Data from NSDQ)

$50.14 USD

50.14
466,690

-2.32 (-4.42%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $50.16 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 250)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Omnicell (OMCL) Down 2.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Investors Should Retain Omnicell (OMCL) Stock Now

by Zacks Equity Research

Investors are optimistic about Omnicell (OMCL) owing to its planned geographic expansion.

Omnicell (OMCL) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Omnicell (OMCL) delivers earnings and revenues in the fourth quarter exceeding the previously revised outlook amid macroeconomic challenges.

Omnicell (OMCL) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 266.67% and 3.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks.com featured highlights Omnicell, Carnival, Atlantica Sustainable Infrastructure and TFS Financial

by Zacks Equity Research

Omnicell, Carnival, Atlantica Sustainable Infrastructure and TFS Financial have been highlighted in this Screen of The Week article.

Rimmi Singhi headshot

Don't Risk Your Hard-Earned Money for These 4 Toxic Stocks

by Rimmi Singhi

Identifying toxic stocks and offloading them at the right time can help you avoid huge losses. OMCL, CCL, AY and TFSL are a few such toxic stocks that you should dump right away.

Zacks.com featured highlights Bally's, Omnicell, Atlantica Sustainable Infrastructure and TFS Financial

by Zacks Equity Research

Bally's, Omnicell, Atlantica Sustainable Infrastructure and TFS Financial have been highlighted in this Screen of The Week article.

10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rimmi Singhi headshot

4 Toxic Stocks That May Not Let You Prosper

by Rimmi Singhi

If you own toxic stocks for long, you are likely to see a big loss in your wealth. Stay away from toxic stocks like BALY, OMCL, AY and TFSL.

Earnings Preview: Omnicell (OMCL) Q4 Earnings Expected to Decline

by Zacks Equity Research

Omnicell (OMCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rimmi Singhi headshot

These 4 Toxic Stocks May Bring Bad Luck to Your Portfolio

by Rimmi Singhi

Consider dumping toxic stocks like BALY, OMCL, ILMN and AY from your portfolio to avoid huge losses.

Do Options Traders Know Something About Omnicell (OMCL) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Omnicell (OMCL) stock based on the movements in the options market lately.

Rimmi Singhi headshot

5 Toxic Stocks That Can Set Off Alarm Bells for Your Portfolio

by Rimmi Singhi

Investors who can correctly spot overpriced stocks and shun them at the right time can avoid big losses. Dump toxic stocks like MGM, ILMN, OMCL, HL and RDNT to prevent portfolio bleeding.

Omnicell (OMCL) Ailed by Mounting Costs, Macroeconomic Issues

by Zacks Equity Research

Macroeconomic factors adversely affect bookings and revenues in Omnicell's (OMCL) point-of-care business. The company reduces its overall bookings and revenue outlook for the year.

Omnicell (OMCL) Q3 Earnings Beat Estimates, Guidance Cut

by Zacks Equity Research

Rise in operating expenses result in an operating loss in Q3 for Omnicell (OMCL), placing significant pressure on the bottom line.

Omnicell (OMCL) Q3 Earnings Top Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of 6.38% and 4.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MDRX vs. OMCL: Which Stock Is the Better Value Option?

by Zacks Equity Research

MDRX vs. OMCL: Which Stock Is the Better Value Option?

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Should iShares S&P SmallCap 600 Growth ETF (IJT) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for IJT

Should SPDR S&P 600 Small Cap Growth ETF (SLYG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLYG

Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down

by Zacks Equity Research

Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.

MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MDRX vs. OMCL: Which Stock Is the Better Value Option?

Omnicell (OMCL) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Omnicell (OMCL) delivered earnings and revenue surprises of -1.18% and 2.37%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SLY

Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.